Is Sanofi destined to be 'small player' in MS?

Sanofi ($SNY) CEO Chris Viehbacher (photo) is talking up trial results on his multiple sclerosis hopeful Lemtrada, acquired in his buyout of Genzyme. But advances by other companies are making it difficult for Sanofi to impress analysts with its own prospects. Report